Exhibit 99.1 IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 ● 30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets ● Major milestones achieved: O Completion of landmark ICE3 trial for breast cancer O Positive final ICE3 trial data ● Awaiting FDA Decision ● Independent studies performed globally continue to demonstrate ProSense®’s efficacy and safety across numerous indications ● Conference call t ...